Congestive heart failure (CHF) is not a disease in itself but a syndrome — the endpoint of various cardiac conditions that leave the heart unable to pump blood efficiently enough to meet the body's needs. When the heart fails to maintain adequate cardiac output, fluid accumulates ("congests") in the lungs, chest cavity, or abdomen, depending on which side of the heart is primarily affected.

In dogs, CHF is divided by affected side:

CHF is extremely common in dogs — estimates suggest it affects up to 11% of all dogs presenting to general practice. The prevalence rises steeply with age: many breeds have a lifetime risk exceeding 30% by age 10–12 years. Understanding this condition empowers owners to recognize early signs, work proactively with their veterinarian, and help their dog live comfortably for months to years after diagnosis.

The two most common underlying cardiac diseases leading to CHF in dogs are:

1. Myxomatous Mitral Valve Disease (MMVD)

MMVD — also called chronic valvular disease, degenerative mitral valve disease, or endocardiosis — accounts for approximately 75–80% of all canine cardiac disease. The mitral valve (between the left atrium and ventricle) progressively thickens, nodulates, and deforms, causing regurgitation (backward blood flow) that increases cardiac workload over years. Eventually, the compensatory mechanisms the heart uses to maintain output — dilation, hypertrophy, increased sympathetic tone — are overwhelmed, and CHF develops.

MMVD follows a staging system developed by the American College of Veterinary Internal Medicine (ACVIM, 2019 guidelines), from Stage A (no disease, at-risk breed) through Stage B1 (murmur, no cardiac changes), B2 (murmur with radiographic/echocardiographic remodeling), and Stage C (current or previous CHF) to Stage D (refractory CHF).

2. Dilated Cardiomyopathy (DCM)

DCM is the primary muscle disease of the heart, characterized by dilation and weakened systolic function of the ventricles. It is the second most common cause of CHF in dogs, accounting for roughly 10–15% of cases.

DCM can also have nutritional components — grain-free diets and diets high in legumes have been linked to an increased incidence of DCM in breeds not typically predisposed, though the mechanism and causality remain under investigation by the FDA.

CHF develops progressively. In the early compensated phase (Stage B), dogs are often completely asymptomatic despite significant cardiac changes — which is why regular veterinary auscultation matters for at-risk breeds. Once compensation fails, clinical signs emerge, and prompt recognition is critical.

The ACVIM 2019 Consensus Guidelines recommend that owners of dogs in Stage B2 MMVD monitor resting respiratory rate at home daily using a stopwatch or a dedicated app (several are available). This simple, free monitoring tool has been shown to detect early CHF decompensation before respiratory distress becomes obvious.

Diagnosing CHF requires integrating clinical findings with imaging and laboratory data. No single test is definitive; the diagnosis is made from the whole picture.

For MMVD, the ACVIM guidelines define the threshold for initiating medical treatment: left atrial-to-aortic ratio (LA:Ao) ≥ 1.6 on echocardiography and/or VHS > 10.5 on radiographs.

Electrocardiogram (ECG) Identifies arrhythmias (atrial fibrillation is common in large-breed DCM and late-stage MMVD). 24-hour Holter monitoring is the standard for Dobermans and Boxers, in which ventricular arrhythmias may be the first manifestation of occult DCM.

Blood Pressure Systemic hypertension can worsen cardiac disease and is checked in all cardiac patients. Renal function (BUN, creatinine, SDMA) and electrolytes are essential before and during diuretic therapy.

CHF management has transformed dramatically in the past decade. Several landmark clinical trials — particularly QUEST (2019) and EPIC (2016) — now guide treatment decisions with strong evidence.

Stage B2 MMVD: Pre-CHF Prevention

The EPIC trial demonstrated that pimobendan (Vetmedin®), started before the onset of CHF in dogs with enlarged hearts (LA:Ao ≥ 1.6 or VHS > 10.5), delayed the onset of CHF by a median of 15 months compared to placebo. This was a landmark finding: it means that at-risk dogs should be screened with echocardiography at their annual wellness visits, and treatment should begin before symptoms appear.

Stage C CHF: Active Congestive Failure

Once CHF is diagnosed, the cornerstone three-drug protocol is:

1. Furosemide (Lasix®) — a loop diuretic that removes excess fluid from the lungs and body. Typically started at 1–2 mg/kg every 12 hours and titrated based on response and kidney function monitoring. Without furosemide, acute CHF is fatal.

1. Pimobendan (Vetmedin®) — an inodilator that simultaneously increases cardiac contractility (positive inotrope) and reduces cardiac afterload (vasodilator). The QUEST trial in MMVD showed pimobendan significantly extended survival compared to benazepril.

1. An RAAS inhibitor — typically an ACE inhibitor such as enalapril or benazepril at 0.25–0.5 mg/kg every 12 hours. Reduces angiotensin II and aldosterone, decreasing fluid retention and cardiac remodeling. In refractory cases, spironolactone (an aldosterone antagonist) is added.

Monitoring Schedule

Medical management of CHF is only one component of comprehensive care. Nutrition and lifestyle modifications significantly affect quality of life and disease progression.

Sodium Restriction

Sodium promotes fluid retention through renal mechanisms. While severe sodium restriction is rarely needed in early CHF (and can actually worsen RAAS activation if too aggressive), moderate restriction is recommended for dogs in Stage C–D. This means avoiding high-sodium human foods, processed treats, and table scraps. Many commercial therapeutic cardiac diets (e.g., Hill's h/d, Royal Canin Cardiac) provide appropriate sodium levels with palatability maintained.

Important: Never feed salty human foods, deli meats, cheese, or snack foods to a dog with CHF.

Maintaining Lean Body Weight

Both obesity and cachexia (muscle wasting) worsen outcomes. Cardiac cachexia — progressive muscle loss in dogs with advanced CHF — results from cytokine-mediated catabolism, reduced appetite, and poor nutrient absorption. If your dog is losing weight, work with your veterinarian on calorie-dense, protein-rich diets (prescription or otherwise) to maintain muscle mass.

Omega-3 Fatty Acids

Fish oil supplementation (EPA + DHA, 40 mg/kg/day combined) has evidence for modest anti-inflammatory and anti-cachexia benefits in dogs with CHF. It also has mild antiarrhythmic properties. Use pharmaceutical-grade fish oil supplements formulated for pets or humans and verify dose with your veterinarian.

Exercise

Dogs with well-compensated CHF benefit from gentle, low-impact exercise — leash walks are appropriate. Avoid strenuous runs, off-leash play with other dogs, and activities requiring sustained aerobic effort. The goal is to maintain muscle tone and mobility without stressing the heart.

As CHF advances, activity will self-limit. Follow your dog's cues: if they want to stop, stop.

Stress Minimization

Stress is profoundly detrimental in cardiac patients — catecholamine release increases heart rate and contractile demand. Minimize travel, changes in routine, and situations that cause anxiety. Discuss anti-anxiety medications with your veterinarian if your dog is prone to stress reactions.

Water Access

Always provide free access to fresh water. Dogs on furosemide lose water through increased urination; dehydration and electrolyte imbalances (particularly hypokalemia) are real risks. If your dog is drinking excessively or very little, report this promptly.

CHF is a manageable but progressive condition. Prognosis varies considerably based on underlying cause, stage at diagnosis, and response to treatment.

Refractory Stage D CHF

Quality of Life Assessment

CHF is one condition where close partnership with your veterinary team — particularly a board-certified cardiologist if referral is possible — makes a measurable difference in both length and quality of life.